Yeh Chun-Nan, Jan Yi-Yin, Yeh Ta-Sen, Hwang Tsann-Long, Chen Miin-Fu
Department of Surgery, Chang Gung Memorial Hospital, 5 Fu-Hsing Street, Kwei-Shan, Taoyuan, Taiwan.
Ann Surg Oncol. 2004 Jun;11(6):606-11. doi: 10.1245/ASO.2004.04.028.
Peripheral cholangiocarcinoma (PCC) can be grossly classified into mass-forming, periductal-infiltrating, and intraductal papillary (IP) types. Information on IP-PCC patients undergoing hepatectomy is sparse because of the small number of cases.
The clinical features of 40 IP-PCC patients undergoing hepatectomy between 1977 and 2000 were reviewed. The clinical features of 94 PCC patients without IP growth undergoing hepatectomy were used for comparison.
IP-PCC and non-IP-PCC groups had similar age distributions (P =.674), sex ratios (P =.079), and positive rates for serum carcinoembryonic antigen and CA 19-9 (P =.121 and.795, respectively). The two groups also exhibited similar rates of association between hepatolithiasis and PCC (P =.230). However, more IP-PCC patients exhibited signs during admission, and more had ALT values >36 IU/L; they also had smaller tumors, more mucobilia association, and tumors in earlier stages and had undergone more postoperative chemotherapy. Multivariate logistic regression analysis showed that only ALT >36 IU/L differentiated IP-PCC from non-IP-PCC patients. The two groups exhibited similar operative mortality (P = 1.0). Follow-up ranged from 1.6 to 125.2 months (mean and median, 44.6 and 5.7 months, respectively). The 1-, 3-, and 5-year overall survival rates were 72.9%, 41.2%, and 24.7%, respectively, in the IP-PCC group and 43.3, 6.03%, and 2.01% in the non-IP-PCC group. The prognosis was favorable for the IP-PCC patients (P <.00001), particularly for IP-PCC patients who received curative hepatectomy (P =.013).
IP-PCC patients had significantly better survival than non-IP-PCC patients, and aggressive curative hepatic resection is associated with a longer survival.
肝外胆管癌(PCC)大体上可分为肿块型、胆管周围浸润型和导管内乳头状(IP)型。由于病例数量较少,关于接受肝切除术的IP-PCC患者的信息较为匮乏。
回顾了1977年至2000年间40例接受肝切除术的IP-PCC患者的临床特征。将94例未发生IP生长的接受肝切除术的PCC患者的临床特征用于比较。
IP-PCC组和非IP-PCC组在年龄分布(P = 0.674)、性别比(P = 0.079)以及血清癌胚抗原和CA 19-9阳性率(分别为P = 0.121和0.795)方面相似。两组在肝内胆管结石与PCC的关联率方面也相似(P = 0.230)。然而,更多的IP-PCC患者在入院时有症状,更多患者的ALT值>36 IU/L;他们的肿瘤较小,更多伴有黏液性胆汁,肿瘤处于早期阶段,且接受术后化疗的比例更高。多因素逻辑回归分析显示,只有ALT>36 IU/L可区分IP-PCC患者与非IP-PCC患者。两组的手术死亡率相似(P = 1.0)。随访时间为1.6至125.2个月(平均和中位数分别为44.6个月和5.7个月)。IP-PCC组的1年、3年和5年总生存率分别为72.9%、41.2%和24.7%,非IP-PCC组分别为43.3%、6.03%和2.01%。IP-PCC患者的预后较好(P < 0.00001),特别是接受根治性肝切除术的IP-PCC患者(P = 0.013)。
IP-PCC患者的生存率明显高于非IP-PCC患者,积极的根治性肝切除与更长的生存期相关。